HIV/AIDS in Central Africa: pathogenesis, immunological and medical issues.
The estimated worldwide prevalence of human immunodeficiency virus (HIV) infections topped 52.5 million in June 2003, a mere 20 years after the aetiological agent was shown to be a sexually transmissible virus with a predilection for CD4+ T lymphocytes. More than 22 million people have died of the acquired immunodeficiency syndrome (AIDS) and the condition has in one generation become the most devastating and persistent epidemics in recorded history. More than two thirds of the world total of HIV-infected people live in Sub-Saharan Africa. In Central and Southern Africa at least 20% of the adult population is infected. As these adults die, they leave increasing numbers of orphans. Life expectancy at birth declined by 10 years per decade since the late 1980s to 50 years in the late 1990s, and in Botswana it is estimated to be as low as 33 years by 2010. The epidemic is increasing unabated and prospects for a curative or protective vaccine remain remote. The impact on HIV in Africa has been so profound that it influences political, economic, agriculture/food security, social, education, defence, science and health considerations. The medical and in particular immunology communities in Central Africa have the invidious challenge of on the one hand diagnosing the condition, monitoring its impact and contributing to treatment and management efforts. The science and clinical practice of immunology is challenged to find answers to the epidemic, perhaps including a vaccine. In this review we address the peculiarities of the HIV epidemic in Africa, its epidemiology and immunopathogenesis. We address the effect of the epidemic on individual patients, in their homes, workplaces and the knock-on effects on families and friends of the infected. Respective specialists discuss special groups (women, children) that are predominantly seen in Africa. We also discuss the impact of the epidemic on the clinical practice of medicine in general and challenges faced in the introduction of antiretroviral medicines. We also discuss options available for the diagnosis, treatment and monitoring of HIV-infected patients in this region.
Sibanda
Elopy Nimele
EN
Department of Immunology, University of Zimbabwe College of Medicine, Harare, Zimbabwe. esibanda@africaonline.co.zw
Stanczuk
Grazyna
G
Kasolo
Francis
F
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D000350:Africa, Central; D002648:Child; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D006678:HIV / Q000145:classification / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D010349:Patient Compliance; D011247:Pregnancy